Tonix to Present Programs for PTSD, Fibromyalgia Drug Candidate at European Conference

Tonix to Present Programs for PTSD, Fibromyalgia Drug Candidate at European Conference
Tonix Pharmaceuticals, a company dedicated to developing next-gen medicines for fibromyalgia and post-traumatic stress disorder (PTSD), announced its Executive Vice President of Commercial Planning and Development, Ronald Notvest, Ph.D., MBA, will present at the 10th Annual BIO Europe Spring Conference in Sweden. Notvest’s presentation will provide a corporate update and a general overview of Tonix Pharmaceuticals’ fibromyalgia and PTSD clinical programs. Tonix is currently evaluating the drug candidate TNX-102 SL, an FDA Investigational New Drug, in: A randomized, double-blind, placebo-controlled, 12-week Phase 3 AFFIRM clinical trial in fibromyalgia, titled “A Study to Evaluate eFFIcacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With fibRoMyalgia (AFFIRM)," with top-line data expected to be reported in the third quarter of 2016; A randomized, double-blind, placebo-controlled, registration-quality Phase 2 AtEase clinical trial in military-related PTSD, titled “Safety and Efficacy Study of TNX-102 SL in Subjects With Military-Related PTSD and Related Conditions (AtEase)" – top-line data is expected to be reported in the last half of May 2016. According to a press release, the presentation will be at 4:45 p.m. Central European Time on Tuesday, April 5, at the Kistamässan Convention Center in Stockholm, Sweden. Tonix Pharmaceuticals is working to develop next-generation medicines for common central nervous system disorders such as fibromyalgia and PTSD. These conditions still have inadequate treatment options for chronic disability and their recurrence rate poses an economic challenge to healthcare providers. Fibromyalgia is one of the most common musculoskeletal conditions, often misdiagnosed and misu
Subscribe or to access all post and page content.